Study subject
primary esophageal motility disorders, heartburn, malignancy, acid regurgitation, active gastric or, Zollinger-Ellison syndrome, Barrett’s esophagus, duodenal ulcer
ESOPHAGEAL DYSPLASIA, GASTROINTESTINAL BLEEDING, ZOLLINGER-ELLISON SYNDROME, INFLAMMATORY BOWEL DISEASE
Male and female patients aged 19–75 years were eligible for inclusion if they had endoscopically confirmed EE based on the Los Angeles (LA) Classification (grades A–D). Additionally, patients had to experience symptoms of acid regurgitation and/or heartburn 7 days prior to the screening visit.The exclusion criteria for the study were as follows: (1) patients who had taken PPI and histamine receptor 2 blocking agent within 2 weeks before the screening endoscopy, (2) patients with active gastric or duodenal ulcer, gastrointestinal bleeding, primary esophageal motility disorders, Zollinger-Ellison syndrome, inflammatory bowel disease, malignancy, and endoscopic Barrett’s esophagus more than 3 cm or esophageal dysplasia, (3) patients who had undergone previous major abdominal surgery, and (4) patients with abnormal laboratory findings at the screening (MDRD eGFR ≤ 59 mL/min/1.73 m